GILD  Gilead Sciences Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

88.24B

Vuru Grade

92.50/100

Current Price

$67.51
+0.02 (+0.03%)

Growth Price

$158.03
Undervalued by 134.08%

Stability Price

$45.53
Overvalued by 32.56%

Company Metrics

  • P/E 6.79
  • P/S 2.9
  • P/B 4.68
  • EPS 9.94
  • Cash ROIC 44.12%
  • Cash Ratio 1.29
  • Dividend 2.08 / 3.07%
  • Avg. Vol. 10.60M
  • Shares 1.31B
  • Market Cap. 88.24B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

The Best-Case Scenario for Gilead Sciences, Inc.
Motley Fool - Mar 24, 2017
Gilead Sciences surprised many observers with a dismal outlook for hepatitis C virus (HCV) drug sales in 2017. The company hasn't been able to answer an all-important question: When will HCV sales stabilize? I don't know the answer to that question ...
What to Expect from Gilead Sciences, Inc. (GILD) Amid M&A Buzz and Upcoming ... - Smarter Analyst
Gilead defended at Jefferies - Seeking Alpha
3 Numbers That Make Gilead Sciences, Inc. Look Cheaper Than It Really Is
Motley Fool - Mar 16, 2017
Shares of Gilead Sciences (NASDAQ:GILD) are trading at levels last seen in the first half of 2014, when trailing-12-month revenue and earnings were substantially lower than they are today.
Better Buy: Biogen Inc. vs. Gilead Sciences Inc.
Motley Fool - Feb 27, 2017
Biogen (NASDAQ:BIIB) and Gilead Sciences (NASDAQ:GILD) don't compete against each other -- at least not yet. Both biotechs are interested in the oncology and autoimmune disease therapeutic areas, so there's always a chance they could become rivals.
What I'm Doing With My Gilead Sciences Shares - Seeking Alpha
Gilead Sciences to Present at the Barclays Global Healthcare Conference on ... - Yahoo Finance
Here's Why the Best Is Yet to Come for Gilead Sciences, Inc.
Motley Fool - Mar 7, 2017
Several of its most promising pipeline prospects are still years away from commercialization. All of these statements are true for Gilead Sciences (NASDAQ:GILD). But is the big biotech destined for perpetual malaise? Not hardly. Here's why the best is ...
Gilead Sciences: Just Any Deal Won't Do - Barron's (blog)
Gilead: Milligan's Response
Seeking Alpha - Mar 21, 2017
The session featured Barclays' senior biotech analyst, Geoff Meacham, who had recently butted to the top tier of the "Gilead (NASDAQ:GILD) must act" chorus. Now he was kicking off his company's vaunted global healthcare conference with a one-on-one ...
Marketplace Roundtable: Biotech Hanging In The Balance
Seeking Alpha - 12 hours ago
Five Marketplace authors focusing on the sector shared their thoughts on the regulatory environment, the industry itself, and what they're watching for in the next few months.
Gilead Sciences Inc. - Receive News & Ratings Daily - BBNS
Trading Vision: Active Stock Focus on Shares of Gilead Sciences, Inc. (NASDAQ ... - Melville Review
I don't think Gilead offers a compelling risk/reward, despite the stock is ...
Seeking Alpha - Mar 23, 2017
Thus, in this article, I will focus on a quantitative valuation of the company using a DCF analysis and without taking into account any potential M&A that Gilead could announce in 2017, which looks unpredictable, to assess if the market has already ...
3 M&A Scenarios For Gilead Sciences
Seeking Alpha - Mar 13, 2017
One of the bigger stories in Biotech Land last week was the increasing pressure Gilead Sciences is coming under from well-known analysts to do something on the M&A front.
Gilead Sciences, Inc. (GILD) Ex-Dividend Date Scheduled for March 14, 2017 - Nasdaq
Is It Time to Sell Gilead Sciences (GILD)? - Smarter Analyst
When It Rains, It Pours For Gilead
Seeking Alpha - Mar 16, 2017
The company is reeling from the demise of its vaunted HCV franchise. According ... Gilead's Sovaldi and Ono and Bristol-Myers (NYSE:BMY) Opdivo are among the drugs selected for another round of reviews and could potentially face even more reductions.
Gilead Sciences Heading South?
Seeking Alpha - Mar 1, 2017
Gilead Sciences is still a great company with a war chest of capital waiting to be deployed, unlocking future growth.
Gilead Sciences: M&A to the Rescue? - Barron's (blog)
Gilead Sciences, Inc. (GILD) Rating Lowered to Buy at Vetr Inc. - Chaffey Breeze
Growth Rate Assumed by Market

We did a reverse valuation to calculate the growth rate the market is assuming for GILD to be considered fairly valued at its current market price. It's useful to compare this to the growth rate we're assuming for the Growth Price.

Future Free Cash Flow Growth Rate

This is the annual growth rate we've applied to calculate GILD's Free Cash Flow for the next 10 years. To calculate it, we looked at several time periods of the last 10 years. Feel free to adjust it, but we limit the initial growth rate to 20% and slow it down over the years. Otherwise, long-term sustainability issues come into play.

Discount Rate

The discount rate is the annual rate of return an investor requires to take the risk of investing in a single stock. To account for that risk, this should be above 8-10%, as this is the avg. annual rate of return for the S&P500 over the past 100 years.

$67.51 Current Price

$158.03 Growth Price (DCF)

Undervalued by 134.08%


Growth Rate Assumed by Market: -10.31%


Future Free Cash Flow Growth Rate: 15.0%


Discount Rate: 15.0%


Show Free Cash Flow numbers

$45.53 Stability Price (EPV)

Overvalued by 32.56%


Discount Rate: 15.0%

$144.04 Book Price

Undervalued by 113.36%


Varying Cash Return on Invested Capital over the past 5 years

GILD has efficiently invested its financial resources in buildings, projects, and equipment, resulting in strong returns. However, there is a substantial variation in their Cash ROIC from year-to-year. This company may have unreliable free cash flow or operates in a business where invested capital costs increase substantially on a sporadic basis. Look at reasons for this inconsistency to determine the likelihood of future sustainability.

GILD has created $44.12 of cash for every $100 invested.
Figures in USD. Fiscal year ends in December
20122013201420152016
Free Cash Flow 2.80B 2.91B 12.26B 19.58B 15.92B
divided by
Invested Capital 15.11B 14.04B 18.78B 27.34B 35.86B
Cash ROIC 18.52% 20.76% 65.30% 71.62% 44.39%

Varying Return on Equity over the past 5 years

GILD has generated strong profits with money shareholders have invested. However, there is a substantial variation in their Return on Equity from year-to-year. This may reflect management's inability to generate consistent returns or may be caused by one-time events. Look at reasons for this inconsistency to determine the likelihood of future sustainability.

GILD has generated $60.36 of Earnings for every $100 of Shareholders' Equity.
Figures in USD. Fiscal year ends in December
20122013201420152016
Net Income 2.57B 3.06B 12.06B 18.11B 13.49B
divided by
Stockholders' Equity 9.31B 11.37B 15.43B 18.53B 18.89B
Return on Equity 27.64% 26.89% 78.17% 97.69% 71.41%

Excellent Business Performance over the past 10 years

GILD has been able to maintain profitability in good times and bad. This could mean GILD has an extremely strong business or has the ability to scale down costs when needed. This should be a fairly resilient business, but double check for future sustainability by looking at its Risk Factors in the Annual Report.

GILD has created positive free cash flow for 9 or more of the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Free Cash Flow 1.69B 2.09B 2.85B 2.77B 3.51B 2.80B 2.91B 12.26B 19.58B 15.92B

Weak Balance Sheet

GILD's financial position is not ideal. The key is to check whether GILD is using debt to fuel its growth and the sustainability of that tendency. Highly capital intensive businesses (see Economic Moat) follow this route, which can deeply impact the future prospects of the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Cash 1.17B 1.79B 1.66B 2.10B 9.90B 1.86B 2.13B 10.13B 14.61B 11.90B
Current Assets 3.03B 4.30B 4.81B 5.71B 13.92B 6.16B 7.27B 17.71B 24.76B 20.45B
Total Assets 5.83B 7.02B 9.70B 11.59B 17.30B 21.24B 22.50B 34.66B 51.84B 56.98B
Current Liabilities 736.28M 1.22B 1.87B 2.46B 2.51B 4.27B 6.33B 5.76B 9.89B 9.22B
Total Liabilities 2.37B 2.87B 3.33B 5.73B 10.56B 11.93B 11.13B 19.24B 33.31B 38.09B
Stockholder' Equity 3.46B 4.15B 6.37B 5.86B 6.74B 9.31B 11.37B 15.43B 18.53B 18.89B
Current Ratio 4.11 3.52 2.57 2.32 5.53 1.44 1.15 3.07 2.50 2.22
TL-to-TA 0.41 0.41 0.34 0.49 0.61 0.56 0.49 0.55 0.64 0.67

Consistent Reinvestment of Profits over the past 10 years

GILD has consistently retained profits. This may put GILD in a strong position to invest for the future, by buying new machinery, investing in R&D or a number of other options. By effectively using these earnings, GILD can greatly improve their long-term economic picture.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Retained Earnings 249.08M 382.87M 2.00B 1.18B 1.78B 3.70B 6.11B 12.73B 18.00B 18.15B
Retained Earnings Growth - 53.72% 421.13% -40.67% 50.10% 108.51% 64.80% 108.54% 41.38% 0.85%

Varying Competitive Advantage over the past 10 years

GILD likely has a competitive advantage which prevents other companies from entering or competing in their industry. However, there is a substantial variation in their Net Profit Margins from year-to-year, which indicates inconsistent performance. Look at reasons for this inconsistency to determine the likelihood of future sustainability.

$38.55 of every $100 of Revenue have been pure profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Net Income 1.62B 2.01B 2.64B 2.90B 2.80B 2.57B 3.06B 12.06B 18.11B 13.49B
divided by
Revenue 4.23B 5.34B 7.01B 7.95B 8.39B 9.70B 11.20B 24.89B 32.64B 30.39B
Net Profit Margin 38.19% 37.69% 37.59% 36.50% 33.43% 26.53% 27.29% 48.45% 55.47% 44.38%

Strong Pricing Power over the past 10 years

GILD has maintained substantial gross margins, suggesting that they have been able to set prices without consideration of the cost of goods sold. This potentially leaves flexibility in inflationary environments to raise prices on consumers and maintain profitability.

$80.73 of every $100 worth of sales have been Gross Profit, on average over the past 10 years.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Gross Profit 3.46B 4.21B 5.42B 6.08B 7.16B 7.23B 8.34B 21.10B 28.63B 26.13B
divided by
Revenue 4.23B 5.34B 7.01B 7.95B 8.39B 9.70B 11.20B 24.89B 32.64B 30.39B
Gross Margin 81.83% 78.87% 77.24% 76.48% 85.34% 74.53% 74.48% 84.78% 87.73% 85.98%

Low Capital Intensity over the past 10 years

GILD has consistently used a small portion of their Net Income buying new equipment or investing in new facilities. This indicates that GILD may require minimal investment to stay competitive. This leaves them with extra money to spend on growing their business and potentially buying back stock.

6.21% of Profits are being spent on Capital Expenditures, like Property, Plant, & Equipment, required to run the business.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Capital Expenditure 78.65M 115.01M 230.06M 61.88M 131.90M 397.05M 190.78M 557.00M 747.00M 748.00M
divided by
Net Income 1.62B 2.01B 2.64B 2.90B 2.80B 2.57B 3.06B 12.06B 18.11B 13.49B
Capital Expenditure Ratio 4.87% 5.72% 8.73% 2.13% 4.70% 15.43% 6.24% 4.62% 4.13% 5.55%

No Dividend History over the past 10 years

GILD has never distributed dividends or has recently suspended their dividend distribution.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Dividend Paid - - - - - - - - - -
divided by
Shares Outstanding 964.36M 958.83M 934.11M 873.40M 790.12M 3.17B 1.69B 1.65B 1.52B 1.36B
Dividend Paid Per Share - - - - - - - - - -
Price at Year End 46.33 51.33 43.80 36.26 40.93 72.38 75.08 95.30 102.16 71.61
Dividend Yield - - - - - - - - - -

Strong History of Stock Buybacks over the past 10 years

GILD has a strong history of delivering increased value for shareholders in the form of stock buybacks. These have helped improve financial metrics and increase each shareholders' relative ownership stake in the company, due to fewer shares outstanding and holding the same number of shares.
Figures in USD. Fiscal year ends in December
2007200820092010201120122013201420152016
Shares Outstanding 964.36M 958.83M 934.11M 873.40M 790.12M 3.17B 1.69B 1.65B 1.52B 1.36B
Stock Bought Back - 0.58% 2.65% 6.95% 10.54% -75.04% 86.76% 2.90% 8.28% 12.00%
Share your thoughts about GILD

Sign Up or Log In to start contributing!


Discussion
Sort By:
1
Posted by pbanik  (on January 29, 2017)
1
Posted by pbanik  (on October 15, 2014)
Deutsche Bank Says Gilead Sciences Stock Reaction Is Overdone
http://www.benzinga.com/analyst-ratings/analyst-color/14/10/4921188/deutsche-bank-says-gilead-sciences-stock-reaction-is-ove

Key stats and ratios
Q2 (Jun '14) 2013
Net profit margin 55.86% 27.29%
Operating margin 67.53% 40.39%
EBITD margin - 43.46%
Return on average assets 49.40% 13.98%
Return on average equity 99.48% 29.75%
Employees 6,100 -
CDP Score
https://www.google.ca/finance?q=gild&ei=avQ9VImFNaauiAKi_ICICQ








- -
1
Posted by tmuscat27  (on April 8, 2013)
you forgot the reason as to why the hep c will not be a winner.
tx tm
1
Posted by Alexleroi  (on February 2, 2013)
Three things to consider: 1) Executive Compensation is unreasonable; 2) Directors have been there for too long, governance red flag;3) Unreasonable acquisitions.
1
Posted by miller  (on March 30, 2012)
They paid one third of their market cap for Pharmassets - $11 billion! That seems irresponsible on first glance. I can't imagine that this hepatitis C drug that Pharmassets has created will be that much of a winner.

Any thoughts?
4
Posted by gsanta111  (on April 17, 2012)
That's when I decided to sell my positions on GILD. Didn't make sense to me. Seems like a huge gamble on a single product
0
Posted by gsanta111  (on March 8, 2013)
Wow, boy was I wrong!

Btw, price is NOT $44.95.

They had a 2-for-1 stock split
So, it's actually at $89.9